Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Pancreatic Neoplasms × poly(I).poly(c12,U) × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 3 Colorectal Neoplasms 3 Breast Neoplasms 2 Recurrence 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Ovarian Cancer Recurrent 1 Neoplasm Metastasis 1 Melanoma 1 Hematologic Neoplasms 1 Fallopian Tube Neoplasms 1 Breast Neoplasms, Male 1 Breast Carcinoma In Situ 1

Interventions

Gemcitabine 367 Oxaliplatin 115 Fluorouracil 112 130-nm albumin-bound paclitaxel 96 Capecitabine 86 Albumin-Bound Paclitaxel 82 Leucovorin 81 Irinotecan 79 Radiotherapy 70 Taxes 59 Radiosurgery 56 Cisplatin 53 Erlotinib Hydrochloride 40 folfirinox 35 Magnetic Resonance Spectroscopy 34 Drug Therapy 34 pembrolizumab 33 S 1 (combination) 30 Blood Specimen Collection 30 Bevacizumab 29 Nivolumab 27 Docetaxel 27 Pancreaticoduodenectomy 25 Cyclophosphamide 24 irinotecan sucrosofate 23 Biopsy 23 Specimen Handling 22 Surgical Procedures, Operative 21 Radiation 19 Electroporation 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05927142 2025-02-25

DURIPANC

Erasmus Medical Center

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡